Go to the list of all blogs
Serhii Bondarenko's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
Cellyan Biotechnology (HKPD) Drops -31% in 30 Days and -83% Over the Quarter

Cellyan Biotechnology (HKPD) Drops -31% in 30 Days and -83% Over the Quarter

Key Takeaways

  • HKPD is the common stock of Cellyan Biotechnology Co., Ltd (formerly Hong Kong Pharma Digital Technology Holdings), a Hong Kong-based over-the-counter (OTC) pharmaceutical cross-border e-commerce supply chain operator — not an exchange-traded fund (ETF).
  • The share price has declined roughly 31% over the last 30 days, from about $2.04 to about $1.40.
  • The decline over the last quarter is far steeper at roughly 83%, from about $8.32 to about $1.40.
  • Primary catalysts include a delayed annual report (20-F) filing, Nasdaq minimum-bid-price compliance concerns, and extreme micro-cap volatility.
  • Healthcare and pharmaceutical distribution exposure, a small float, and concentrated insider ownership amplify price swings in both directions.
  • For additional context on this ticker's outlook, review its Price Targets and Forecast on dedicated pages.
  • Investors can also explore Trending AI Robots for automated trading and signal ideas.

Understanding Cellyan Biotechnology's Business Model

Cellyan Biotechnology Co., Ltd operates as a Nasdaq-listed common stock rather than any kind of fund. Headquartered in Yau Tong, Hong Kong, the company focuses on OTC pharmaceutical cross-border procurement, distribution, and e-commerce supply chain services that link Hong Kong with Mainland China. Its activities split into supply chain services via the Joint Cross Border subsidiary and procurement and distribution through V-Alliance.

This remains a micro-cap issuer with roughly 27 full-time employees and revenues in the low tens of millions, alongside a trailing net loss. Ownership stays heavily concentrated among insiders and founders, while institutional holdings are limited. With no underlying index or portfolio, HKPD trades as a single small-cap equity, which explains much of its sharp volatility.

Reviewing HKPD's Recent Price Action

Over the past 30 days, HKPD has dropped approximately 31%, moving from a close near $2.04 down to around $1.40. The path has been uneven, featuring abrupt declines interrupted by modest recoveries that reflect thin trading volumes and high volatility.

The quarterly view looks even more challenging. Three months earlier the shares changed hands near $8.32, so the stock has shed roughly 83% of its value in that period. A single-session plunge in early September on heavy volume initiated the steepest part of the move, after which prices continued lower in a stepwise manner.

Drivers Behind the 30-Day Move

Company-specific issues stand out as the main influences rather than broader sector trends. The delayed 20-F annual report filing has raised questions around governance and transparency, pressuring investor sentiment. At the same time, ongoing Nasdaq minimum-bid-price compliance requirements add another layer of uncertainty tied to potential delisting risks.

These pressures interact with the stock's micro-cap characteristics: a limited float, modest liquidity, and concentrated ownership allow even moderate selling to trigger large percentage changes. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Broader healthcare and pharmaceutical distribution trends appear secondary here.

Factors Behind the Quarterly Decline

The three-month trend reflects a sustained re-rating driven by repeated disclosure and listing-compliance matters. The early-September selloff on elevated volume signaled a clear shift in risk perception, after which the shares struggled to find stable footing. Limited institutional interest and a short public-company history since the January 2025 listing left the stock exposed to further pressure.

From a wider perspective, tighter liquidity and greater scrutiny of listing compliance for small-cap and foreign issuers created a difficult environment. Still, the scale of HKPD's decline ties most directly to issuer-specific fundamentals and structure.

Key Developments to Monitor Going Forward

Several company-specific and structural elements deserve close attention in the months ahead. Resolution of the delayed 20-F filing and a return to timely reporting will matter a great deal, along with any progress on Nasdaq minimum-bid-price compliance. Reverse-split developments or extensions of grace periods could also prove significant.

Revenue trends in the OTC pharmaceutical cross-border e-commerce segment, along with margin and cash-flow progress given the current net-loss position, warrant watching. Shifts in the concentrated insider ownership base and macroeconomic factors such as China cross-border demand, logistics costs, and regulatory changes in pharmaceutical distribution remain relevant as well. These elements are likely to dominate price action more than general market direction.

Using Tickeron Tools for Deeper Analysis

In my own research process, I often turn to Tickeron’s AI Screener when evaluating micro-cap names like this one. The platform lets users apply technical indicators, fundamentals, volatility measures, and AI signals across thousands of securities, making it easier to compare momentum and risk profiles in a systematic way. It has helped me surface comparable opportunities and refine filters without relying solely on manual review.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: HKPD

Contributor

Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.


Momentum Indicator for HKPD turns negative, indicating new downward trend

HKPD saw its Momentum Indicator move below the 0 level on October 28, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator turned negative. In 26 of the 27 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HKPD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for HKPD entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where HKPD's RSI Indicator exited the oversold zone, 12 of 14 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +15.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where HKPD advanced for three days, in 57 of 65 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.

HKPD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.566) is normal, around the industry mean (14.423). P/E Ratio (6.136) is within average values for comparable stocks, (11.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.016). Dividend Yield (0.000) settles around the average of (0.134) among similar stocks. P/S Ratio (0.147) is also within normal values, averaging (4.260).

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. HKPD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HKPD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock worse than average.

Notable companies

The most notable companies in this group are McKesson Corp (NYSE:MCK).

Industry description

Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.

Market Cap

The average market capitalization across the Medical Distributors Industry is 23.75B. The market cap for tickers in the group ranges from 44.8K to 123.68B. MCK holds the highest valuation in this group at 123.68B. The lowest valued company is COCM at 44.8K.

High and low price notable news

The average weekly price growth across all stocks in the Medical Distributors Industry was -3%. For the same Industry, the average monthly price growth was -23%, and the average quarterly price growth was -27%. MEDS experienced the highest price growth at 80%, while ACH experienced the biggest fall at -35%.

Volume

The average weekly volume growth across all stocks in the Medical Distributors Industry was 325%. For the same stocks of the Industry, the average monthly volume growth was 539% and the average quarterly volume growth was 207%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 48
Price Growth Rating: 61
SMR Rating: 88
Profit Risk Rating: 73
Seasonality Score: 3 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry MedicalDistributors

Industry
N/A
Address
13 Ko Fai Road
Phone
+852 26189289
Employees
11
Web
http://www.9zt.hk
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.